AU2004230952A1 - Beta-carbolines useful for treating inflammatory disease - Google Patents

Beta-carbolines useful for treating inflammatory disease Download PDF

Info

Publication number
AU2004230952A1
AU2004230952A1 AU2004230952A AU2004230952A AU2004230952A1 AU 2004230952 A1 AU2004230952 A1 AU 2004230952A1 AU 2004230952 A AU2004230952 A AU 2004230952A AU 2004230952 A AU2004230952 A AU 2004230952A AU 2004230952 A1 AU2004230952 A1 AU 2004230952A1
Authority
AU
Australia
Prior art keywords
aliphatic
hydrogen
pct
halo
amino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2004230952A
Other languages
English (en)
Inventor
Alfredo Castro
Paul E. Fleming
Michael E. Hepperle
Jeremy D. Little
Julie Fields Liu
Hormoz Mazdiyasni
Robert S. Murray
Raman Prakash
Dominic Reynolds
Francois Soucy
Yingchun Ye
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Millennium Pharmaceuticals Inc
Original Assignee
Millennium Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Millennium Pharmaceuticals Inc filed Critical Millennium Pharmaceuticals Inc
Publication of AU2004230952A1 publication Critical patent/AU2004230952A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/30—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
AU2004230952A 2003-04-09 2004-04-09 Beta-carbolines useful for treating inflammatory disease Abandoned AU2004230952A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US46146803P 2003-04-09 2003-04-09
US60/461,468 2003-04-09
PCT/US2004/011080 WO2004092167A1 (en) 2003-04-09 2004-04-09 Beta-carbolines useful for treating inflammatory disease

Publications (1)

Publication Number Publication Date
AU2004230952A1 true AU2004230952A1 (en) 2004-10-28

Family

ID=33299818

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2004230952A Abandoned AU2004230952A1 (en) 2003-04-09 2004-04-09 Beta-carbolines useful for treating inflammatory disease

Country Status (22)

Country Link
US (2) US7727985B2 (https=)
EP (1) EP1611134A1 (https=)
JP (1) JP2006522824A (https=)
KR (1) KR20060006031A (https=)
CN (1) CN1802375A (https=)
AU (1) AU2004230952A1 (https=)
BR (1) BRPI0409263A (https=)
CA (1) CA2521300A1 (https=)
CO (1) CO5700746A2 (https=)
CR (1) CR8042A (https=)
EA (1) EA009121B1 (https=)
EC (1) ECSP056145A (https=)
HR (1) HRP20050926A2 (https=)
MA (1) MA27837A1 (https=)
MX (1) MXPA05010793A (https=)
NI (1) NI200500174A (https=)
NO (1) NO20054598L (https=)
OA (1) OA13115A (https=)
RS (1) RS20050832A (https=)
TN (1) TNSN05257A1 (https=)
WO (1) WO2004092167A1 (https=)
ZA (1) ZA200508198B (https=)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0409263A (pt) 2003-04-09 2006-03-28 Millennium Pharm Inc composto; composição farmacêutica; método para tratar uma doença mediada por ikk e método para inibir ikk em um paciente que dele necessita
BRPI0509660A (pt) * 2004-04-09 2007-10-09 Millennium Pharm Inc compostos de beta-carbolina de utilidade no tratamento de doenças inflamatórias
US8119655B2 (en) * 2005-10-07 2012-02-21 Takeda Pharmaceutical Company Limited Kinase inhibitors
JP5249772B2 (ja) * 2005-11-22 2013-07-31 メルク・シャープ・アンド・ドーム・コーポレーション キナーゼの阻害剤として有用な三環式化合物
EP2001455A2 (en) 2006-03-15 2008-12-17 Theralogics, Inc. Methods of treating muscular wasting diseases using nf-kb activation inhibitors
WO2008002246A1 (en) * 2006-06-28 2008-01-03 Astrazeneca Ab A pharmaceutical composition comprising an ikk2 inhibitor and a second active ingrdient.
EP2125841A1 (en) * 2006-12-13 2009-12-02 Gilead Sciences, Inc. Monophosphates as mutual prodrugs of anti-inflammatory signal transduction modulators (aistm's) and beta-agonists for the treatment of pulmonary inflammation and bronchoconstriction
US20090131422A1 (en) * 2007-10-23 2009-05-21 Millennium Pharmaceuticals, Inc. Salts of an IKK inhibitor
US20090137579A1 (en) * 2007-10-23 2009-05-28 Millennium Pharmaceuticals, Inc. Mesylate salt of an IKK inhibitor
US20110111417A1 (en) 2008-05-14 2011-05-12 Millennium Pharmaceuticals, Inc. Methods and kits for monitoring the effects of immunomodulators on adaptive immunity
EP2366699B1 (en) 2008-10-02 2013-08-07 Asahi Kasei Pharma Corporation 8-substituted isoquinoline derivative and use thereof
KR101461767B1 (ko) 2010-03-30 2014-11-13 노파르티스 아게 만성 활성 ｂ-세포-수용체 신호전달이 있는 ｂ-세포 림프종의 치료를 위한 ｐｋｃ 억제제
CN103596949A (zh) * 2011-03-28 2014-02-19 Sjt分子研究有限公司 用于代谢综合征的治疗的化合物
CN102416014B (zh) * 2011-09-13 2012-11-21 河南中医学院 一种生物碱类成分组合物在制备抗甲型h1n1流感病毒药物中的应用
CN102391323B (zh) * 2011-10-18 2013-09-25 首都医科大学 四氢-β-咔啉衍生物、其制备方法及其用途
KR101646916B1 (ko) 2015-07-13 2016-08-09 강원대학교산학협력단 베타-카르볼린 알칼로이드 화합물을 함유하는 염증성 질환의 예방 또는 치료용 조성물
WO2017067670A1 (en) 2015-10-23 2017-04-27 Pharmathen S.A. A novel process for the preparation of tryptamines and derivatives thereof
CN109593089B (zh) * 2019-01-24 2022-01-28 西南大学 二氮杂螺癸烷哌啶甲酰胺类化合物制备和应用
CN112824387B (zh) * 2019-11-21 2023-03-21 济南尚博生物科技有限公司 一种2-甲基烟酸酯及其制备方法和应用
CN117510494B (zh) * 2023-11-07 2024-04-19 桂林医学院附属医院 β-咔啉-沙利度胺偶联物及其在制备逆转ABT-199耐药的药物中的应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2242402T3 (es) * 1998-08-12 2005-11-01 Pfizer Products Inc. Inhibidores de tace.
DE19951360A1 (de) * 1999-10-26 2001-05-03 Aventis Pharma Gmbh Substituierte Indole
HK1054039B (zh) * 2000-03-15 2010-04-16 萨诺费－阿文蒂斯德国有限公司 取代的β-咔啉
EP1268477B1 (en) * 2000-03-15 2010-04-21 Sanofi-Aventis Deutschland GmbH Substituted beta-carbolines with ikb-kinase inhibiting activity
ATE363473T1 (de) * 2001-09-19 2007-06-15 Pharmacia Corp Substituierte pyrazoloverbindungen zur behandlung von entzündungen
US9248124B2 (en) * 2001-11-07 2016-02-02 Millennium Pharmaceuticals, Inc. Use of inhibitors of IκB kinase for the treatment of cancer
US7396943B2 (en) * 2003-03-07 2008-07-08 Eli Lilly And Company Opioid receptor antagonists
BRPI0409263A (pt) 2003-04-09 2006-03-28 Millennium Pharm Inc composto; composição farmacêutica; método para tratar uma doença mediada por ikk e método para inibir ikk em um paciente que dele necessita

Also Published As

Publication number Publication date
TNSN05257A1 (en) 2007-07-10
OA13115A (en) 2006-11-10
WO2004092167A8 (en) 2006-01-05
MA27837A1 (fr) 2006-04-03
NO20054598L (no) 2005-10-27
EA009121B1 (ru) 2007-10-26
EA200501584A1 (ru) 2006-06-30
BRPI0409263A (pt) 2006-03-28
ECSP056145A (es) 2006-04-19
CR8042A (es) 2006-05-30
EP1611134A1 (en) 2006-01-04
CO5700746A2 (es) 2006-11-30
CN1802375A (zh) 2006-07-12
JP2006522824A (ja) 2006-10-05
KR20060006031A (ko) 2006-01-18
WO2004092167A1 (en) 2004-10-28
US20040235839A1 (en) 2004-11-25
RS20050832A (sr) 2007-12-31
HRP20050926A2 (en) 2006-06-30
CA2521300A1 (en) 2004-10-28
US20100093713A1 (en) 2010-04-15
MXPA05010793A (es) 2005-12-05
NO20054598D0 (no) 2005-10-06
NI200500174A (es) 2006-04-17
ZA200508198B (en) 2007-01-31
US7727985B2 (en) 2010-06-01

Similar Documents

Publication Publication Date Title
US20100093713A1 (en) Beta-carbolines useful for treating inflammatory disease
JP7679173B2 (ja) Ｒａｆ（急速進行性線維肉腫）ポリペプチドの標的分解のための化合物および方法
AU2024203200A1 (en) Bifunctional molecules containing an e3 ubiquitine ligase binding moiety linked to a bcl6 targeting moiety
EP3231798B1 (en) Thiazole intermediates useful in the preparation of raf kinase inhibitors
US7951801B2 (en) Beta-carbolines useful for treating inflammatory disease
CA3214806A1 (en) Modulators of bcl6 proteolysis and associated methods of use
AU2017304761C1 (en) Pharmaceutical compounds
KR20190101406A (ko) Egfr 단백질분해 표적화 키메라 분자 및 관련 사용 방법
KR20190113842A (ko) 에스트로겐 수용체 단백질 분해 조절제 및 관련 사용 방법
AU2014240388A1 (en) Substituted 7-azabicycles and their use as orexin receptor modulators
NZ749946A (en) Novel compound or pharmaceutically acceptable salt thereof
CA2608672A1 (en) Pyridine [3,4-b] pyrazinones as pde-5 inhibitors
US20050245563A1 (en) Chk-1 inhibitors
WO2005118583A1 (en) 2, 5-dihydro-pyrazolo`4, 3-c!quinolin-4-ones as chk-1 inhibitors
WO2009067233A1 (en) Beta carbolines and uses thereof
CN117561262A (zh) 大环tak1抑制剂
AU2014200030A1 (en) Pyrimidine Derivatives Useful as Raf Kinase Inhibitors

Legal Events

Date Code Title Description
MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application